Details of the Drug Combination

General Information of Drug Combination (ID: DCWOZPY)

• Drug Combination Name: Etoposide + Lapatinib
• Indication: Malignant melanoma; Status: Investigative [1]
• Component Drugs:
  Etoposide (DMNH3PG): Small molecular drug
  Lapatinib (DM3BH1Y): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: SKMEL30
  Zero Interaction Potency (ZIP) Score: 1.94
  Bliss Independence Score: 7.6
  Loewe Additivity Score: 4.8
  LHighest Single Agent (HSA) Score: 8.5

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Etoposide

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Approved	[2]
Adult acute monocytic leukemia	N.A.	Approved	[2]
Adult kidney Wilms tumor	N.A.	Approved	[2]
Beckwith-Wiedemann syndrome	N.A.	Approved	[2]
Childhood kidney Wilms tumor	N.A.	Approved	[2]
Hamartoma	N.A.	Approved	[2]
Kidney neoplasm	N.A.	Approved	[2]
Lung cancer	2C25.0	Approved	[2]
Non-small-cell lung cancer	2C25.Y	Approved	[2]
Plasma cell myeloma	2A83.1	Approved	[2]
Small-cell lung cancer	2C25.Y	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Testicular cancer	2C80	Approved	[4]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[5]
Neuroblastoma	2D11.2	Investigative	[2]

Etoposide Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Modulator	[29]

Etoposide Interacts with 8 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[30]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[31]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[32]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[33]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[34]
Multidrug resistance-associated protein 3 (ABCC3)	DTQ3ZHF	MRP3_HUMAN	Substrate	[35]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[36]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[34]

Etoposide Interacts with 9 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[37]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[37]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[8]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[38]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Metabolism	[39]
Glutathione S-transferase pi (GSTP1)	DEK6079	GSTP1_HUMAN	Metabolism	[40]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Metabolism	[41]
Glutathione S-transferase theta-1 (GSTT1)	DE3PKUG	GSTT1_HUMAN	Metabolism	[40]
Prostaglandin G/H synthase 2 (COX-2)	DE492CE	PGH2_HUMAN	Metabolism	[41]

Etoposide Interacts with 475 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Increases Expression	[42]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[43]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Increases Expression	[43]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Decreases Methylation	[44]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Decreases Response To Substance	[45]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[46]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Decreases Response To Substance	[47]
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Decreases Response To Substance	[45]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Affects Transport	[48]
DNA topoisomerase 2-alpha (TOP2A)	OT6LPS08	TOP2A_HUMAN	Decreases Response To Substance	[49]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[50]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[51]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Increases ADR	[52]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Decreases Response To Substance	[53]
Tumor protein p73 (TP73)	OT0LUO47	P73_HUMAN	Increases Expression	[9]
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial (CYP27B1)	OTTK98BH	CP27B_HUMAN	Increases Expression	[9]
Dihydropyrimidinase-related protein 4 (DPYSL4)	OT3SBS2S	DPYL4_HUMAN	Increases Expression	[10]
Copper chaperone for superoxide dismutase (CCS)	OTXHT3QO	CCS_HUMAN	Increases Expression	[10]
Urokinase-type plasminogen activator (PLAU)	OTX0QGKK	UROK_HUMAN	Increases Expression	[10]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[10]
Ubiquitin-like protein ISG15 (ISG15)	OT53QQ7N	ISG15_HUMAN	Increases Expression	[10]
Integrin alpha-IIb (ITGA2B)	OT4Y17PY	ITA2B_HUMAN	Increases Expression	[10]
Ras-related protein R-Ras (RRAS)	OTBBF28C	RRAS_HUMAN	Increases Expression	[10]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[10]
Stomatin (STOM)	OTC8R6EH	STOM_HUMAN	Increases Expression	[10]
Cellular retinoic acid-binding protein 2 (CRABP2)	OTY01V9G	RABP2_HUMAN	Increases Expression	[10]
Tyrosine-protein kinase receptor UFO (AXL)	OTKA2SUX	UFO_HUMAN	Increases Expression	[10]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Increases Expression	[10]
Galectin-7 (LGALS7)	OTMSVI7R	LEG7_HUMAN	Increases Expression	[10]
Rho GDP-dissociation inhibitor 2 (ARHGDIB)	OT9PD6CS	GDIR2_HUMAN	Increases Expression	[10]
Epithelial membrane protein 1 (EMP1)	OTSZHUHQ	EMP1_HUMAN	Increases Expression	[10]
Epithelial membrane protein 3 (EMP3)	OTODMJ1D	EMP3_HUMAN	Increases Expression	[10]
Protein ripply3 (RIPPLY3)	OT1HK35I	DSCR6_HUMAN	Increases Expression	[10]
Kinesin-like protein KIF1A (KIF1A)	OT3JVEGV	KIF1A_HUMAN	Increases Expression	[10]
Filamin-C (FLNC)	OT3F8J6Y	FLNC_HUMAN	Increases Expression	[10]
Immediate early response gene 5 protein (IER5)	OTJPTXMD	IER5_HUMAN	Increases Expression	[10]
Keratin, type II cytoskeletal 80 (KRT80)	OTAU54U3	K2C80_HUMAN	Increases Expression	[10]
All-trans-retinol 13,14-reductase (RETSAT)	OTC3AOPX	RETST_HUMAN	Increases Expression	[10]
Mitochondria-eating protein (SPATA18)	OTOEHTHU	MIEAP_HUMAN	Increases Expression	[10]
Tumor necrosis factor receptor superfamily member 14 (TNFRSF14)	OTB82PFO	TNR14_HUMAN	Increases Expression	[10]
Major histocompatibility complex class I-related gene protein (MR1)	OTZU3XX7	HMR1_HUMAN	Increases Expression	[10]
Roundabout homolog 3 (ROBO3)	OTPVG40S	ROBO3_HUMAN	Increases Expression	[10]
Neuronal PAS domain-containing protein 1 (NPAS1)	OTZKO6ZN	NPAS1_HUMAN	Increases Expression	[10]
Ankyrin repeat domain-containing protein 10 (ANKRD10)	OTIZ2VK8	ANR10_HUMAN	Decreases Expression	[10]
Serine/threonine-protein kinase PLK2 (PLK2)	OTKMJXJ8	PLK2_HUMAN	Increases Expression	[10]
Solute carrier family 2, facilitated glucose transporter member 6 (SLC2A6)	OTVUZCLG	GTR6_HUMAN	Increases Expression	[10]
Glutaminase liver isoform, mitochondrial (GLS2)	OT08MSHL	GLSL_HUMAN	Increases Expression	[10]
Endothelial protein C receptor (PROCR)	OTRHED17	EPCR_HUMAN	Increases Expression	[10]
Fatty acid desaturase 3 (FADS3)	OT9RVXGE	FADS3_HUMAN	Increases Expression	[10]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Increases Activity	[54]
NADH-ubiquinone oxidoreductase chain 4 (ND4)	OT4RQVAA	NU4M_HUMAN	Increases Expression	[42]
Nitric oxide synthase, inducible (NOS2)	OTKKIOJ1	NOS2_HUMAN	Increases Expression	[42]
Transcription factor A, mitochondrial (TFAM)	OTXXV5V7	TFAM_HUMAN	Increases Expression	[42]
TP53-binding protein 1 (TP53BP1)	OTL8879S	TP53B_HUMAN	Increases Expression	[42]
Peroxisome proliferator-activated receptor gamma coactivator 1-beta (PPARGC1B)	OTN6FKCB	PRGC2_HUMAN	Increases Expression	[42]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A)	OTHCDQ22	PRGC1_HUMAN	Increases Expression	[42]
Calsequestrin-2 (CASQ2)	OT09MNQ8	CASQ2_HUMAN	Decreases Expression	[11]
Telethonin (TCAP)	OTQQMJ94	TELT_HUMAN	Decreases Expression	[11]
LIM domain-binding protein 3 (LDB3)	OTGQL1AM	LDB3_HUMAN	Decreases Expression	[11]
Creatine kinase M-type (CKM)	OTME0KO7	KCRM_HUMAN	Decreases Expression	[11]
Glutathione peroxidase 1 (GPX1)	OTE2O72Q	GPX1_HUMAN	Increases Expression	[11]
Myosin light chain 3 (MYL3)	OTKD3RSX	MYL3_HUMAN	Decreases Expression	[11]
Keratin, type I cytoskeletal 19 (KRT19)	OTDGDQ75	K1C19_HUMAN	Increases Expression	[11]
Calmodulin-1 (CALM2)	OTNYA92F	CALM1_HUMAN	Increases Expression	[11]
Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MYL2)	OT78PC0C	MLRV_HUMAN	Decreases Expression	[11]
Glycogen phosphorylase, muscle form (PYGM)	OTWLVWTV	PYGM_HUMAN	Decreases Expression	[11]
Dystrophin (DMD)	OTD21T5J	DMD_HUMAN	Decreases Expression	[11]
Myosin-7 (MYH7)	OT4Z9T8N	MYH7_HUMAN	Decreases Expression	[11]
Leukemia inhibitory factor (LIF)	OTO46S5S	LIF_HUMAN	Increases Expression	[11]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[11]
Ankyrin-1 (ANK1)	OTU79URK	ANK1_HUMAN	Increases Expression	[11]
Desmin (DES)	OTI09KBW	DESM_HUMAN	Decreases Expression	[11]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[11]
CCN family member 2 (CCN2)	OTC39NSU	CCN2_HUMAN	Increases Expression	[11]
Sodium/calcium exchanger 1 (SLC8A1)	OT787VRN	NAC1_HUMAN	Decreases Expression	[11]
Thrombospondin-4 (THBS4)	OTA1T9KK	TSP4_HUMAN	Increases Expression	[11]
Gap junction alpha-5 protein (GJA5)	OTRMZVO6	CXA5_HUMAN	Decreases Expression	[11]
Vasopressin V1a receptor (AVPR1A)	OTKR8AFL	V1AR_HUMAN	Increases Expression	[11]
Sodium/potassium-transporting ATPase subunit alpha-2 (ATP1A2)	OTCF8OWW	AT1A2_HUMAN	Decreases Expression	[11]
cAMP-dependent protein kinase catalytic subunit PRKX (PRKX)	OTDAC6Z0	PRKX_HUMAN	Increases Expression	[11]
Stanniocalcin-1 (STC1)	OTGVVXYF	STC1_HUMAN	Increases Expression	[11]
Myomesin-2 (MYOM2)	OTD2UOXW	MYOM2_HUMAN	Decreases Expression	[11]
Actin, alpha skeletal muscle (ACTA1)	OTOVGLPG	ACTS_HUMAN	Decreases Expression	[11]
Iroquois-class homeodomain protein IRX-4 (IRX4)	OT0TV6WK	IRX4_HUMAN	Decreases Expression	[11]
Arginase-2, mitochondrial (ARG2)	OTCPI0E8	ARGI2_HUMAN	Decreases Expression	[11]
Cytochrome c oxidase subunit 6A2, mitochondrial (COX6A2)	OTQR5SXD	CX6A2_HUMAN	Decreases Expression	[11]
Pro-neuregulin-1, membrane-bound isoform (NRG1)	OTZO6F1X	NRG1_HUMAN	Increases Expression	[11]
Dual specificity protein phosphatase 4 (DUSP4)	OT6WAO12	DUS4_HUMAN	Increases Expression	[11]
Krueppel-like factor 5 (KLF5)	OT1ABI9N	KLF5_HUMAN	Increases Expression	[11]
Four and a half LIM domains protein 2 (FHL2)	OT0OAYWT	FHL2_HUMAN	Decreases Expression	[11]
Transmembrane glycoprotein NMB (GPNMB)	OTB7KQKV	GPNMB_HUMAN	Increases Expression	[11]
Periostin (POSTN)	OTWP62UA	POSTN_HUMAN	Increases Expression	[11]
kinase isozyme 1, mitochondrial (PDK1)	OTMABK9Z	PDK1_HUMAN	Decreases Expression	[11]
kinase isozyme 4, mitochondrial (PDK4)	OTCMHMBZ	PDK4_HUMAN	Increases Expression	[11]
PDZ and LIM domain protein 3 (PDLIM3)	OTVXQC81	PDLI3_HUMAN	Increases Expression	[11]
Nebulin-related-anchoring protein (NRAP)	OTO6H3YF	NRAP_HUMAN	Decreases Expression	[11]
Sodium channel subunit beta-4 (SCN4B)	OT3JSUWO	SCN4B_HUMAN	Increases Expression	[11]
Actin-binding Rho-activating protein (ABRA)	OTBQ2C1J	ABRA_HUMAN	Increases Expression	[11]
Transient receptor potential cation channel subfamily V member 1 (TRPV1)	OTHHDR03	TRPV1_HUMAN	Increases Expression	[11]
Ryanodine receptor 2 (RYR2)	OT0PF19E	RYR2_HUMAN	Decreases Expression	[11]
Small conductance calcium-activated potassium channel protein 2 (KCNN2)	OTQVTMK5	KCNN2_HUMAN	Decreases Expression	[11]
Regulator of cell cycle RGCC (RGCC)	OTYJMLWM	RGCC_HUMAN	Increases Expression	[11]
Myotilin (MYOT)	OTCEW5XW	MYOTI_HUMAN	Increases Expression	[11]
Protein ATP1B4 (ATP1B4)	OT2YC9GZ	AT1B4_HUMAN	Increases Expression	[11]
Junctional adhesion molecule A (F11R)	OTGHPAV6	JAM1_HUMAN	Increases Expression	[11]
Succinate dehydrogenase assembly factor 1, mitochondrial (SDHAF1)	OTDG5VW7	SDHF1_HUMAN	Decreases Expression	[13]
Agrin (AGRN)	OTWJENAZ	AGRIN_HUMAN	Increases Expression	[12]
E3 ubiquitin-protein ligase TRIM38 (TRIM38)	OT6SP1M9	TRI38_HUMAN	Decreases Expression	[13]
Torsin-1A (TOR1A)	OTYCLGJU	TOR1A_HUMAN	Decreases Expression	[13]
Etoposide-induced protein 2.4 homolog (EI24)	OTD4NOYS	EI24_HUMAN	Increases Expression	[12]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[55]
Tax1-binding protein 3 (TAX1BP3)	OTQ6IB4T	TX1B3_HUMAN	Increases Expression	[12]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	OT9RDS3H	IKKB_HUMAN	Decreases Expression	[56]
Proepiregulin (EREG)	OTRM4NQY	EREG_HUMAN	Increases Expression	[57]
Transcription factor EC (TFEC)	OTUST8MR	TFEC_HUMAN	Decreases Expression	[13]
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK)	OTLF4ZB1	IKKA_HUMAN	Decreases Expression	[56]
Protein phosphatase 1D (PPM1D)	OT8NLZ9D	PPM1D_HUMAN	Increases Expression	[58]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Increases Expression	[59]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Increases Expression	[60]
E3 ubiquitin-protein ligase RNF113A (RNF113A)	OTR6N7HU	R113A_HUMAN	Decreases Expression	[13]
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2)	OT0KMIYQ	RIPK2_HUMAN	Increases Expression	[59]
Krueppel-like factor 4 (KLF4)	OT4O9RQW	KLF4_HUMAN	Increases Expression	[61]
Forkhead box protein O3 (FOXO3)	OTHXQG4P	FOXO3_HUMAN	Increases Phosphorylation	[62]
Cytoplasmic protein NCK2 (NCK2)	OTUYPF55	NCK2_HUMAN	Decreases Expression	[12]
Protein regulator of cytokinesis 1 (PRC1)	OTHD0XS0	PRC1_HUMAN	Decreases Expression	[12]
Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1)	OT80DZMT	BUB1_HUMAN	Decreases Expression	[63]
HMG box-containing protein 1 (HBP1)	OTDPGGDV	HBP1_HUMAN	Decreases Expression	[13]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B)	OT8KME51	BUB1B_HUMAN	Decreases Expression	[63]
Cell division control protein 45 homolog (CDC45)	OT6NNLOD	CDC45_HUMAN	Decreases Expression	[63]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Increases Activity	[64]
Kinesin-like protein KIF20A (KIF20A)	OTXOQHE0	KI20A_HUMAN	Decreases Expression	[13]
Myelin protein zero-like protein 1 (MPZL1)	OTJSUUHR	MPZL1_HUMAN	Decreases Expression	[13]
Serine/threonine-protein kinase Chk2 (CHEK2)	OT8ZPCNS	CHK2_HUMAN	Increases Phosphorylation	[65]
Aldehyde dehydrogenase 1A1 (ALDH1A1)	OTCUWZKB	AL1A1_HUMAN	Increases Expression	[61]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Decreases Expression	[57]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Increases Expression	[66]
Protransforming growth factor alpha (TGFA)	OTPD1LL9	TGFA_HUMAN	Increases Expression	[57]
HLA class I histocompatibility antigen, B alpha chain (HLA-B)	OTNXFWY2	HLAB_HUMAN	Affects Expression	[67]
Transferrin receptor protein 1 (TFRC)	OT8ZPBDL	TFR1_HUMAN	Decreases Expression	[61]
Ferritin light chain (FTL)	OTYQA8A6	FRIL_HUMAN	Increases Expression	[61]
Metallothionein-2 (MT2A)	OTHOACHD	MT2_HUMAN	Decreases Expression	[16]
Interstitial collagenase (MMP1)	OTI4I2V1	MMP1_HUMAN	Decreases Expression	[68]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Increases Expression	[51]
HLA class I histocompatibility antigen, A alpha chain (HLA-A)	OTAH14LU	HLAA_HUMAN	Affects Expression	[67]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Decreases Expression	[57]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Acetylation	[69]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Increases Expression	[43]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Phosphorylation	[70]
Transcription factor Sp1 (SP1)	OTISPT4X	SP1_HUMAN	Increases Phosphorylation	[71]
High mobility group protein B1 (HMGB1)	OT4B7CPF	HMGB1_HUMAN	Increases Secretion	[72]
Annexin A4 (ANXA4)	OTUCRYXL	ANXA4_HUMAN	Increases Expression	[12]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[73]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[74]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Increases Expression	[74]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Increases Degradation	[75]
Cholesteryl ester transfer protein (CETP)	OTAGPPOE	CETP_HUMAN	Increases Expression	[76]
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1)	OTPWI88U	CEAM1_HUMAN	Increases Expression	[12]
Translationally-controlled tumor protein (TPT1)	OTHMTRJU	TCTP_HUMAN	Increases Expression	[77]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Increases Expression	[78]
HLA class I histocompatibility antigen, alpha chain E (HLA-E)	OTX1CTFB	HLAE_HUMAN	Affects Expression	[67]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Decreases Expression	[63]
Protein C-ets-1 (ETS1)	OT4LVGDN	ETS1_HUMAN	Increases Expression	[56]
Amphiregulin (AREG)	OTJFOR67	AREG_HUMAN	Increases Expression	[57]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[79]
Syndecan-1 (SDC1)	OTWKRVZC	SDC1_HUMAN	Increases Expression	[12]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[63]
Receptor tyrosine-protein kinase erbB-3 (ERBB3)	OTRSST0A	ERBB3_HUMAN	Decreases Expression	[57]
rRNA 2'-O-methyltransferase fibrillarin (FBL)	OTRODIE5	FBRL_HUMAN	Affects Localization	[80]
NADPH:adrenodoxin oxidoreductase, mitochondrial (FDXR)	OTPDCK1F	ADRO_HUMAN	Increases Expression	[12]
Brain-derived neurotrophic factor (BDNF)	OTLGH7EW	BDNF_HUMAN	Increases Expression	[81]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)	OTIN6G20	CPT2_HUMAN	Decreases Expression	[13]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Increases Expression	[63]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Increases Expression	[14]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Increases Degradation	[82]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[50]
Tripeptidyl-peptidase 2 (TPP2)	OT91OVAU	TPP2_HUMAN	Affects Localization	[83]
M-phase inducer phosphatase 1 (CDC25A)	OTSLKKCO	MPIP1_HUMAN	Decreases Expression	[13]
M-phase inducer phosphatase 3 (CDC25C)	OTPQI71S	MPIP3_HUMAN	Decreases Expression	[63]
Dual specificity protein kinase TTK (TTK)	OTBY1Z5H	TTK_HUMAN	Decreases Expression	[63]
DNA replication licensing factor MCM7 (MCM7)	OT6FXC6K	MCM7_HUMAN	Decreases Expression	[63]
Replication factor C subunit 1 (RFC1)	OT3L5PK3	RFC1_HUMAN	Decreases Expression	[13]
Tumor necrosis factor receptor superfamily member 3 (LTBR)	OT2HVZGV	TNR3_HUMAN	Increases Expression	[59]
Breast cancer type 1 susceptibility protein (BRCA1)	OT5BN6VH	BRCA1_HUMAN	Decreases Expression	[84]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[63]
Transcription factor ETV6 (ETV6)	OTCZMG61	ETV6_HUMAN	Increases Mutagenesis	[85]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9)	OTV9L89D	TNFL9_HUMAN	Increases Expression	[12]
Serine/threonine-protein kinase mTOR (MTOR)	OTHH8KU7	MTOR_HUMAN	Increases Phosphorylation	[86]
Caspase-2 (CASP2)	OTUDYSPP	CASP2_HUMAN	Increases Expression	[87]
RNA-binding protein 34 (RBM34)	OTX3LUGI	RBM34_HUMAN	Decreases Expression	[13]
DNA repair protein RAD52 homolog (RAD52)	OT0OTDHI	RAD52_HUMAN	Increases Expression	[88]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[62]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3)	OTI2OREX	MP2K3_HUMAN	Increases Expression	[12]
Tumor necrosis factor ligand superfamily member 6 (FASLG)	OTZARCHH	TNFL6_HUMAN	Increases Activity	[89]
Stromal cell-derived factor 1 (CXCL12)	OT2QX5LL	SDF1_HUMAN	Decreases Expression	[90]
Iron-responsive element-binding protein 2 (IREB2)	OT747D24	IREB2_HUMAN	Decreases Expression	[61]
Nuclear receptor-interacting protein 1 (NRIP1)	OTIZOJQV	NRIP1_HUMAN	Decreases Expression	[76]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[91]
Centromere protein F (CENPF)	OT7AG0SW	CENPF_HUMAN	Decreases Expression	[63]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Decreases Expression	[92]
DNA replication licensing factor MCM2 (MCM2)	OTGGORIQ	MCM2_HUMAN	Decreases Expression	[63]
LIM/homeobox protein Lhx2 (LHX2)	OTK61NP8	LHX2_HUMAN	Decreases Expression	[13]
Serine/threonine-protein kinase Nek2 (NEK2)	OT1H27HO	NEK2_HUMAN	Decreases Expression	[63]
DNA mismatch repair protein Msh6 (MSH6)	OT46FP09	MSH6_HUMAN	Decreases Expression	[13]
Death-associated protein kinase 1 (DAPK1)	OTNCNUCO	DAPK1_HUMAN	Increases Expression	[56]
Mitogen-activated protein kinase 12 (MAPK12)	OTTCKE27	MK12_HUMAN	Increases Activity	[93]
RecQ-like DNA helicase BLM (BLM)	OTEJOAJX	BLM_HUMAN	Decreases Expression	[13]
Ataxin-1 (ATXN1)	OTQF0HNR	ATX1_HUMAN	Decreases Expression	[13]
Oxysterols receptor LXR-beta (NR1H2)	OT4APA60	NR1H2_HUMAN	Affects Localization	[76]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[94]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[94]
BH3-interacting domain death agonist (BID)	OTOSHSHU	BID_HUMAN	Increases Expression	[59]
Triosephosphate isomerase (TPI1)	OT14KP4B	TPIS_HUMAN	Increases Phosphorylation	[95]
Small ribosomal subunit protein eS6 (RPS6)	OTT4D1LN	RS6_HUMAN	Increases Phosphorylation	[96]
DNA-dependent protein kinase catalytic subunit (PRKDC)	OTJVS4EG	PRKDC_HUMAN	Increases Phosphorylation	[71]
Protein BTG2 (BTG2)	OTZF6K1H	BTG2_HUMAN	Increases Expression	[13]
Hepcidin (HAMP)	OT607RBL	HEPC_HUMAN	Decreases Expression	[97]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Affects Localization	[51]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Increases Expression	[63]
Runt-related transcription factor 1 (RUNX1)	OTU7J84H	RUNX1_HUMAN	Increases Mutagenesis	[85]
Myelin transcription factor 1 (MYT1)	OTC3660I	MYT1_HUMAN	Decreases Expression	[63]
POU domain, class 5, transcription factor 1 (POU5F1)	OTDHHN7O	PO5F1_HUMAN	Increases Expression	[61]
DNA topoisomerase 2-beta (TOP2B)	OTDHKQZ8	TOP2B_HUMAN	Decreases Activity	[98]
Histone-lysine N-methyltransferase 2A (KMT2A)	OT9GLJI6	KMT2A_HUMAN	Increases Cleavage	[99]
Antigen peptide transporter 1 (TAP1)	OTJL27PW	TAP1_HUMAN	Increases Expression	[12]
CCAAT/enhancer-binding protein zeta (CEBPZ)	OT11BATG	CEBPZ_HUMAN	Decreases Expression	[12]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[63]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Decreases Expression	[62]
Forkhead box protein O1 (FOXO1)	OTPJRB6D	FOXO1_HUMAN	Increases Phosphorylation	[62]
Chromatin assembly factor 1 subunit A (CHAF1A)	OTXSSY4H	CAF1A_HUMAN	Decreases Expression	[13]
Oxysterols receptor LXR-alpha (NR1H3)	OT54YZ9I	NR1H3_HUMAN	Increases Expression	[76]
Serine-protein kinase ATM (ATM)	OTQVOHLT	ATM_HUMAN	Increases Phosphorylation	[100]
DNA topoisomerase 3-alpha (TOP3A)	OT3CKUI9	TOP3A_HUMAN	Decreases Expression	[13]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Decreases Expression	[63]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Increases Expression	[101]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)	OTXEE550	APR_HUMAN	Increases Expression	[53]
Protein BTG3 (BTG3)	OT9ANHVT	BTG3_HUMAN	Decreases Expression	[13]
Histone RNA hairpin-binding protein (SLBP)	OTVYYQRT	SLBP_HUMAN	Decreases Expression	[13]
Hypermethylated in cancer 1 protein (HIC1)	OTI9TWY4	HIC1_HUMAN	Increases Expression	[102]
DNA replication licensing factor MCM6 (MCM6)	OTKLIAWT	MCM6_HUMAN	Decreases Expression	[63]
Receptor tyrosine-protein kinase erbB-4 (ERBB4)	OT9L6C41	ERBB4_HUMAN	Decreases Expression	[57]
Neutral amino acid transporter B(0) (SLC1A5)	OTE2H26Q	AAAT_HUMAN	Decreases Expression	[13]
Mothers against decapentaplegic homolog 2 (SMAD2)	OTC6VB4K	SMAD2_HUMAN	Increases Phosphorylation	[90]
Cyclin-G2 (CCNG2)	OTII38K2	CCNG2_HUMAN	Increases Expression	[103]
Cyclin-dependent kinase inhibitor 3 (CDKN3)	OTBE3H07	CDKN3_HUMAN	Decreases Expression	[63]
Quinone oxidoreductase PIG3 (TP53I3)	OTSCM68G	QORX_HUMAN	Increases Expression	[12]
Ribosomal protein eS27-like (RPS27L)	OTZWHU0N	RS27L_HUMAN	Increases Expression	[104]
Protein MCM10 homolog (MCM10)	OTV0O3JN	MCM10_HUMAN	Decreases Expression	[13]
EPM2A-interacting protein 1 (EPM2AIP1)	OT21ALNF	EPMIP_HUMAN	Increases Expression	[12]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B)	OTE8GBUR	RIR2B_HUMAN	Increases Expression	[105]
Partner and localizer of BRCA2 (PALB2)	OT6DNDBG	PALB2_HUMAN	Decreases Expression	[13]
Jouberin (AHI1)	OT8K2YWY	AHI1_HUMAN	Increases Expression	[106]
Leucine-rich repeat-containing protein 47 (LRRC47)	OTSE8NAO	LRC47_HUMAN	Decreases Expression	[13]
RelA-associated inhibitor (PPP1R13L)	OTNCPLWE	IASPP_HUMAN	Increases Expression	[107]
DNA repair and recombination protein RAD54-like (RAD54L)	OTEGMAKG	RAD54_HUMAN	Increases Expression	[14]
Cytochrome c oxidase assembly factor 7 (COA7)	OTRQJYL6	COA7_HUMAN	Decreases Expression	[13]
Mitochondrial potassium channel (CCDC51)	OTOJNHNA	MITOK_HUMAN	Decreases Expression	[13]
Integrator complex subunit 15 (INTS15)	OT3O4INM	INT15_HUMAN	Decreases Expression	[13]
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Increases Expression	[53]
Proheparin-binding EGF-like growth factor (HBEGF)	OTLU00JS	HBEGF_HUMAN	Increases Expression	[57]
Krueppel-like factor 6 (KLF6)	OTQY9S7F	KLF6_HUMAN	Decreases Expression	[13]
Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)	OTQR6ENW	M3K5_HUMAN	Decreases Expression	[12]
Cell division control protein 6 homolog (CDC6)	OTX93FE7	CDC6_HUMAN	Decreases Expression	[63]
Growth/differentiation factor 15 (GDF15)	OTWQN50N	GDF15_HUMAN	Increases Expression	[63]
SOSS complex subunit B1 (NABP2)	OTQU8081	SOSB1_HUMAN	Increases Acetylation	[108]
Protein pelota homolog (PELO)	OTF3WLIM	PELO_HUMAN	Decreases Expression	[13]
TIMELESS-interacting protein (TIPIN)	OT9PZHXV	TIPIN_HUMAN	Decreases Expression	[13]
Cell cycle regulator of non-homologous end joining (CYREN)	OT5ZL00R	CYREN_HUMAN	Affects Localization	[109]
Caspase recruitment domain-containing protein 10 (CARD10)	OT2RPM4I	CAR10_HUMAN	Increases Expression	[59]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Decreases Expression	[110]
Sulfiredoxin-1 (SRXN1)	OTYDBO4L	SRXN1_HUMAN	Increases Expression	[111]
tRNA pseudouridine(38/39) synthase (PUS3)	OT6WG6M2	PUS3_HUMAN	Decreases Expression	[13]
Homeodomain-interacting protein kinase 2 (HIPK2)	OTDB7QC3	HIPK2_HUMAN	Increases Activity	[81]
Serine/threonine-protein kinase PLK3 (PLK3)	OT19CT2Z	PLK3_HUMAN	Increases Expression	[12]
Transmembrane protein 185B (TMEM185B)	OTGNYS0J	T185B_HUMAN	Decreases Expression	[13]
Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2)	OT3Q11WQ	I20L2_HUMAN	Decreases Expression	[13]
GrpE protein homolog 1, mitochondrial (GRPEL1)	OT8O00YJ	GRPE1_HUMAN	Decreases Expression	[13]
Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A)	OT5V52LN	TNR12_HUMAN	Increases Expression	[59]
Programmed cell death 1 ligand 1 (CD274)	OTJ0VFDL	PD1L1_HUMAN	Increases Expression	[112]
Forkhead box protein J2 (FOXJ2)	OTPT639J	FOXJ2_HUMAN	Decreases Expression	[13]
rRNA methyltransferase 2, mitochondrial (MRM2)	OTRYA1HU	MRM2_HUMAN	Decreases Expression	[13]
DNA helicase MCM8 (MCM8)	OTC93H3S	MCM8_HUMAN	Decreases Expression	[63]
Frizzled-1 (FZD1)	OTZATHVS	FZD1_HUMAN	Decreases Expression	[13]
Calcium-binding protein 39 (CAB39)	OT2CL9ST	CAB39_HUMAN	Decreases Expression	[12]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)	OT1OG4QZ	AAKB1_HUMAN	Increases Expression	[13]
Sestrin-1 (SESN1)	OTSFDZWL	SESN1_HUMAN	Increases Expression	[13]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Decreases Response To Substance	[113]
Molybdenum cofactor sulfurase (MOCOS)	OT0TL3Q5	MOCOS_HUMAN	Affects Response To Substance	[18]
Tripartite motif-containing protein 2 (TRIM2)	OT0V1YVC	TRIM2_HUMAN	Affects Response To Substance	[18]
V-type proton ATPase 116 kDa subunit a 4 (ATP6V0A4)	OT149Z7Q	VPP4_HUMAN	Affects Response To Substance	[18]
Insulin-like growth factor-binding protein 7 (IGFBP7)	OT1D416P	IBP7_HUMAN	Affects Response To Substance	[18]
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Affects Response To Substance	[18]
D-3-phosphoglycerate dehydrogenase (PHGDH)	OT1LMRTG	SERA_HUMAN	Affects Response To Substance	[18]
Calcipressin-1 (RCAN1)	OT1MVXC7	RCAN1_HUMAN	Affects Response To Substance	[18]
Melanoma antigen recognized by T-cells 1 (MLANA)	OT1N2S2K	MAR1_HUMAN	Affects Response To Substance	[18]
Serine palmitoyltransferase small subunit A (SPTSSA)	OT2PNKOP	SPTSA_HUMAN	Affects Response To Substance	[18]
Large neutral amino acids transporter small subunit 1 (SLC7A5)	OT2WPVXD	LAT1_HUMAN	Affects Response To Substance	[18]
Chitinase-3-like protein 1 (CHI3L1)	OT2Z7VJH	CH3L1_HUMAN	Decreases Response To Substance	[114]
Syncytin-2 (ERVFRD-1)	OT3064D7	SYCY2_HUMAN	Affects Response To Substance	[18]
DNA-directed RNA polymerase I subunit RPA12 (POLR1H)	OT30S3SB	RPA12_HUMAN	Decreases Response To Substance	[115]
Protein FAM171A1 (FAM171A1)	OT33BHEP	F1711_HUMAN	Affects Response To Substance	[18]
Fatty acid CoA ligase Acsl3 (ACSL3)	OT3MWER1	ACSL3_HUMAN	Affects Response To Substance	[18]
Platelet-derived growth factor C (PDGFC)	OT3ZJ0XU	PDGFC_HUMAN	Affects Response To Substance	[18]
Insulin receptor substrate 2 (IRS2)	OT46MJBE	IRS2_HUMAN	Affects Response To Substance	[18]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Affects Response To Substance	[18]
Proteinase-activated receptor 1 (F2R)	OT4WVWBO	PAR1_HUMAN	Affects Response To Substance	[18]
Roundabout homolog 1 (ROBO1)	OT52UFVS	ROBO1_HUMAN	Affects Response To Substance	[18]
DNA repair nuclease/redox regulator APEX1 (APEX1)	OT53OI14	APEX1_HUMAN	Decreases Response To Substance	[116]
Lymphokine-activated killer T-cell-originated protein kinase (PBK)	OT5Z27TW	TOPK_HUMAN	Affects Response To Substance	[18]
Protein E7 (E7)	OT6BIMFN	VE7_HPV16	Increases ADR	[52]
G-protein-signaling modulator 2 (GPSM2)	OT6RPMRM	GPSM2_HUMAN	Affects Response To Substance	[18]
CD40 ligand (CD40LG)	OT75Z6A6	CD40L_HUMAN	Decreases Response To Substance	[117]
Monocarboxylate transporter 7 (SLC16A6)	OT7BIIZX	MOT7_HUMAN	Affects Response To Substance	[18]
Homeobox protein engrailed-2 (EN2)	OT7EZCM2	HME2_HUMAN	Affects Response To Substance	[18]
Ras-related protein Rab-17 (RAB17)	OT7NBUGQ	RAB17_HUMAN	Affects Response To Substance	[18]
Fibroblast growth factor 2 (FGF2)	OT7YUJ9F	FGF2_HUMAN	Affects Response To Substance	[18]
Myelin proteolipid protein (PLP1)	OT8CM9CX	MYPR_HUMAN	Affects Response To Substance	[18]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Increases Response To Substance	[118]
Phosphatidylinositol 4-phosphate 5-kinase type-1 beta (PIP5K1B)	OT8JQ1F7	PI51B_HUMAN	Affects Response To Substance	[18]
Neuronal membrane glycoprotein M6-b (GPM6B)	OT8Q1582	GPM6B_HUMAN	Affects Response To Substance	[18]
Melanoma-associated antigen 12 (MAGEA12)	OT8ULELL	MAGAC_HUMAN	Affects Response To Substance	[18]
Solute carrier family 22 member 18 (SLC22A18)	OT9C3KR4	S22AI_HUMAN	Affects Response To Substance	[18]
Thymosin beta-4 (TMSB4X)	OT9HPLP3	TYB4_HUMAN	Decreases Response To Substance	[119]
Follicle-stimulating hormone receptor (FSHR)	OT9MVMLI	FSHR_HUMAN	Increases ADR	[120]
Oxidoreductase HTATIP2 (HTATIP2)	OT9MZ4QO	HTAI2_HUMAN	Affects Response To Substance	[18]
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 (ST6GALNAC2)	OT9PBQVT	SIA7B_HUMAN	Affects Response To Substance	[18]
Splicing factor 45 (RBM17)	OT9ROJCL	SPF45_HUMAN	Decreases Response To Substance	[121]
CD44 antigen (CD44)	OT9TTJ41	CD44_HUMAN	Affects Response To Substance	[122]
Retinoblastoma tumor suppressor (RB1)	OT9VMY7B	Q5J3Q9_FUNHE	Increases ADR	[52]
Tissue factor pathway inhibitor (TFPI)	OTA0FX16	TFPI1_HUMAN	Affects Response To Substance	[18]
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADM)	OTA4P0FC	ACADM_HUMAN	Affects Response To Substance	[18]
POM121 and ZP3 fusion protein (POMZP3)	OTAH2JOK	POZP3_HUMAN	Affects Response To Substance	[18]
Transmembrane protein 47 (TMEM47)	OTAJ4CPX	TMM47_HUMAN	Affects Response To Substance	[18]
Glutathione S-transferase theta-2 (GSTT2)	OTANW3TJ	GST2_HUMAN	Affects Response To Substance	[18]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)	OTAYZZE6	AL3A1_HUMAN	Affects Response To Substance	[123]
5-hydroxytryptamine receptor 4 (HTR4)	OTBIB44K	5HT4R_HUMAN	Affects Response To Substance	[18]
High mobility group protein HMGI-C (HMGA2)	OTBMBHHL	HMGA2_HUMAN	Affects Response To Substance	[18]
Chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1)	OTBML9D9	CGAT1_HUMAN	Affects Response To Substance	[18]
Microtubule-associated tumor suppressor 1 (MTUS1)	OTBPALMU	MTUS1_HUMAN	Affects Response To Substance	[18]
Cystathionine gamma-lyase (CTH)	OTC90LA0	CGL_HUMAN	Affects Response To Substance	[18]
Melanocyte protein PMEL (PMEL)	OTCDDHHM	PMEL_HUMAN	Affects Response To Substance	[18]
BMP and activin membrane-bound inhibitor homolog (BAMBI)	OTCEJ8W5	BAMBI_HUMAN	Affects Response To Substance	[18]
Alkaline phosphatase, germ cell type (ALPG)	OTCIM29R	PPBN_HUMAN	Affects Response To Substance	[18]
Creatine kinase U-type, mitochondrial (CKMT1A)	OTCINHH5	KCRU_HUMAN	Affects Response To Substance	[18]
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1)	OTCJ458Q	AT1A1_HUMAN	Affects Response To Substance	[18]
Ras-interacting protein 1 (RASIP1)	OTCRY2AN	RAIN_HUMAN	Affects Response To Substance	[18]
Collagen alpha-3(IX) chain (COL9A3)	OTCUJOEK	CO9A3_HUMAN	Affects Response To Substance	[18]
A-kinase anchor protein 12 (AKAP12)	OTCVRDDX	AKA12_HUMAN	Affects Response To Substance	[18]
Interferon-stimulated gene 20 kDa protein (ISG20)	OTCWRJJW	ISG20_HUMAN	Affects Response To Substance	[18]
Stathmin (STMN1)	OTDJ4RV0	STMN1_HUMAN	Affects Response To Substance	[124]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Increases Response To Substance	[125]
Dickkopf-related protein 3 (DKK3)	OTDU94EY	DKK3_HUMAN	Affects Response To Substance	[18]
P protein (OCA2)	OTDWIGBF	P_HUMAN	Affects Response To Substance	[18]
Cystatin-SN (CST1)	OTE4I83Q	CYTN_HUMAN	Affects Response To Substance	[18]
Alternative prion protein (PRNP)	OTE85L1Q	APRIO_HUMAN	Decreases Response To Substance	[126]
Fructose-bisphosphate aldolase C (ALDOC)	OTEC13I5	ALDOC_HUMAN	Affects Response To Substance	[18]
Interferon-induced transmembrane protein 1 (IFITM1)	OTECO1G8	IFM1_HUMAN	Affects Response To Substance	[18]
Epidermal growth factor-like protein 8 (EGFL8)	OTECTJ7K	EGFL8_HUMAN	Affects Response To Substance	[18]
dTDP-D-glucose 4,6-dehydratase (TGDS)	OTEOFLOS	TGDS_HUMAN	Affects Response To Substance	[18]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Increases ADR	[52]
Ras association domain-containing protein 1 (RASSF1)	OTEZIPB7	RASF1_HUMAN	Increases Response To Substance	[127]
Transcription factor SOX-10 (SOX10)	OTF25ULQ	SOX10_HUMAN	Affects Response To Substance	[18]
Eukaryotic translation initiation factor 3 subunit A (EIF3A)	OTFABY9G	EIF3A_HUMAN	Increases Response To Substance	[128]
Sortilin (SORT1)	OTFCQ4B1	SORT_HUMAN	Affects Response To Substance	[18]
Kelch-like ECH-associated protein 1 (KEAP1)	OTFHOD0C	KEAP1_HUMAN	Increases Response To Substance	[113]
Myelin basic protein (MBP)	OTFZCEDB	MBP_HUMAN	Affects Response To Substance	[18]
Protein AF1q (MLLT11)	OTG5RVHC	AF1Q_HUMAN	Affects Response To Substance	[18]
Tudor domain-containing protein 3 (TDRD3)	OTG83E2C	TDRD3_HUMAN	Affects Response To Substance	[18]
Enhancer of filamentation 1 (NEDD9)	OTGCFN4M	CASL_HUMAN	Affects Response To Substance	[18]
Squalene synthase (FDFT1)	OTGDISIT	FDFT_HUMAN	Affects Response To Substance	[18]
Voltage-gated potassium channel subunit beta-2 (KCNAB2)	OTH115IE	KCAB2_HUMAN	Affects Response To Substance	[18]
Dual specificity protein phosphatase 2 (DUSP2)	OTH54FMR	DUS2_HUMAN	Affects Response To Substance	[18]
Sigma intracellular receptor 2 (TMEM97)	OTH76ZWK	SGMR2_HUMAN	Affects Response To Substance	[18]
Melanoma-associated antigen C1 (MAGEC1)	OTHMFHH8	MAGC1_HUMAN	Affects Response To Substance	[18]
Tribbles homolog 2 (TRIB2)	OTHSX3MX	TRIB2_HUMAN	Affects Response To Substance	[18]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Affects Response To Substance	[18]
BAG family molecular chaperone regulator 2 (BAG2)	OTI6LD27	BAG2_HUMAN	Affects Response To Substance	[18]
Nucleosome assembly protein 1-like 1 (NAP1L1)	OTI7WBZV	NP1L1_HUMAN	Affects Response To Substance	[18]
Melanoma-associated antigen 6 (MAGEA6)	OTI8S0O2	MAGA6_HUMAN	Affects Response To Substance	[18]
Prosaposin receptor GPR37 (GPR37)	OTIMDDI3	GPR37_HUMAN	Affects Response To Substance	[18]
Kynureninase (KYNU)	OTINL2RE	KYNU_HUMAN	Affects Response To Substance	[18]
Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA)	OTIOLNHE	LICH_HUMAN	Affects Response To Substance	[18]
Baculoviral IAP repeat-containing protein 7 (BIRC7)	OTITCGHB	BIRC7_HUMAN	Decreases Response To Substance	[129]
Runt-related transcription factor 3 (RUNX3)	OTITK1XD	RUNX3_HUMAN	Increases Response To Substance	[130]
Protein S100-P (S100P)	OTJCXNJG	S100P_HUMAN	Increases Response To Substance	[131]
Osteopontin (SPP1)	OTJGC23Y	OSTP_HUMAN	Affects Response To Substance	[18]
cAMP-responsive element modulator (CREM)	OTJIJ5AL	CREM_HUMAN	Affects Response To Substance	[18]
Alpha-(1,6)-fucosyltransferase (FUT8)	OTJJCVG1	FUT8_HUMAN	Affects Response To Substance	[18]
Trefoil factor 3 (TFF3)	OTJJDRTU	TFF3_HUMAN	Affects Response To Substance	[18]
Transcription factor-like 5 protein (TCFL5)	OTJL4348	TCFL5_HUMAN	Affects Response To Substance	[18]
Uncharacterized protein C4orf19 (C4ORF19)	OTJMU7N6	CD019_HUMAN	Affects Response To Substance	[18]
Sorbin and SH3 domain-containing protein 2 (SORBS2)	OTJSX44Y	SRBS2_HUMAN	Affects Response To Substance	[18]
Myc box-dependent-interacting protein 1 (BIN1)	OTK8O0X8	BIN1_HUMAN	Increases Response To Substance	[132]
Transmembrane channel-like protein 6 (TMC6)	OTKH50J4	TMC6_HUMAN	Affects Response To Substance	[18]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Affects Response To Substance	[133]
B-cell receptor-associated protein 31 (BCAP31)	OTKSACR4	BAP31_HUMAN	Increases ADR	[52]
Myelin P2 protein (PMP2)	OTKYV2NE	MYP2_HUMAN	Affects Response To Substance	[18]
Cytochrome P450 26A1 (CYP26A1)	OTL1DFWV	CP26A_HUMAN	Decreases Response To Substance	[134]
Histone-binding protein RBBP7 (RBBP7)	OTLB56HX	RBBP7_HUMAN	Increases ADR	[52]
Glycylpeptide N-tetradecanoyltransferase 2 (NMT2)	OTLNA39Z	NMT2_HUMAN	Affects Response To Substance	[18]
Tyrosine-protein kinase Fyn (FYN)	OTLSLVZS	FYN_HUMAN	Affects Response To Substance	[18]
Homeobox protein Hox-A5 (HOXA5)	OTLWGPQD	HXA5_HUMAN	Affects Response To Substance	[18]
DNA cytosine-5)-methyltransferase 1 (DNMT1)	OTM2DGTK	DNMT1_HUMAN	Decreases Response To Substance	[135]
Lymphocyte antigen 6E (LY6E)	OTMG16BZ	LY6E_HUMAN	Affects Response To Substance	[18]
Bridging integrator 3 (BIN3)	OTMIWWDW	BIN3_HUMAN	Affects Response To Substance	[18]
Bcl-2-like protein 2 (BCL2L2)	OTMKVO0J	B2CL2_HUMAN	Decreases Response To Substance	[136]
Histone-lysine N-methyltransferase 2B (KMT2B)	OTMMAZQX	KMT2B_HUMAN	Increases ADR	[52]
Copper-transporting ATPase 1 (ATP7A)	OTMR3GXP	ATP7A_HUMAN	Decreases Response To Substance	[137]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Increases Response To Substance	[138]
Protein kinase C zeta type (PRKCZ)	OTN2FE42	KPCZ_HUMAN	Increases Response To Substance	[139]
Four and a half LIM domains protein 1 (FHL1)	OTN535SU	FHL1_HUMAN	Affects Response To Substance	[18]
Epithelial splicing regulatory protein 1 (ESRP1)	OTNCS4SL	ESRP1_HUMAN	Affects Response To Substance	[18]
Beta-secretase 2 (BACE2)	OTO5YQVK	BACE2_HUMAN	Affects Response To Substance	[18]
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B)	OTOA8WU2	PDE4B_HUMAN	Affects Response To Substance	[18]
Hypoxanthine-guanine phosphoribosyltransferase (HPRT1)	OTOEEEXG	HPRT_HUMAN	Increases ADR	[52]
Myeloperoxidase (MPO)	OTOOXLIN	PERM_HUMAN	Increases Metabolism	[140]
Glutathione S-transferase Mu 4 (GSTM4)	OTOTF8DU	GSTM4_HUMAN	Affects Response To Substance	[18]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Increases Response To Substance	[62]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Decreases Response To Substance	[27]
Ras-related protein Rab-20 (RAB20)	OTP9OOVS	RAB20_HUMAN	Affects Response To Substance	[18]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C)	OTPL0AI1	ABC3C_HUMAN	Affects Response To Substance	[18]
Epithelial membrane protein 2 (EMP2)	OTPS2H0L	EMP2_HUMAN	Affects Response To Substance	[18]
Ropporin-1A (ROPN1)	OTPXKZTX	ROP1A_HUMAN	Affects Response To Substance	[18]
Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP)	OTPYQX3K	C1QBP_HUMAN	Decreases Response To Substance	[141]
Cyclic GMP-AMP phosphodiesterase SMPDL3A (SMPDL3A)	OTQDYH8E	ASM3A_HUMAN	Affects Response To Substance	[18]
Histone deacetylase 4 (HDAC4)	OTQNGD32	HDAC4_HUMAN	Affects Response To Substance	[18]
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A (ANKRD28)	OTRBREQ9	ANR28_HUMAN	Affects Response To Substance	[18]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Response To Substance	[142]
Disabled homolog 2 (DAB2)	OTRMQTMZ	DAB2_HUMAN	Affects Response To Substance	[18]
Large ribosomal subunit protein eL6 (RPL6)	OTRU71O4	RL6_HUMAN	Decreases Response To Substance	[143]
Band 4.1-like protein 3 (EPB41L3)	OTS6CHG2	E41L3_HUMAN	Affects Response To Substance	[18]
Glutathione S-transferase Mu 1 (GSTM1)	OTSBF2MO	GSTM1_HUMAN	Affects Response To Substance	[28]
Heat shock-related 70 kDa protein 2 (HSPA2)	OTSDET7B	HSP72_HUMAN	Affects Response To Substance	[18]
MyoD family inhibitor domain-containing protein (MDFIC)	OTSRYBWZ	MDFIC_HUMAN	Affects Response To Substance	[18]
Terminal nucleotidyltransferase 5A (TENT5A)	OTSYF511	TET5A_HUMAN	Affects Response To Substance	[18]
Collagen alpha-1(XV) chain (COL15A1)	OTTFKK18	COFA1_HUMAN	Affects Response To Substance	[18]
Bcl-2-interacting killer (BIK)	OTTH1T3D	BIK_HUMAN	Increases Response To Substance	[144]
Serine/threonine-protein kinase Chk1 (CHEK1)	OTTTI622	CHK1_HUMAN	Affects Response To Substance	[145]
Max-interacting protein 1 (MXI1)	OTUQ9E0D	MXI1_HUMAN	Affects Response To Substance	[18]
Calcium-dependent secretion activator 2 (CADPS2)	OTV1FW0M	CAPS2_HUMAN	Affects Response To Substance	[18]
Forkhead box protein F2 (FOXF2)	OTV20NGX	FOXF2_HUMAN	Affects Response To Substance	[18]
Metastasis-associated in colon cancer protein 1 (MACC1)	OTV3DLX0	MACC1_HUMAN	Increases ADR	[120]
Glutathione S-transferase LANCL1 (LANCL1)	OTVCMZXB	LANC1_HUMAN	Affects Response To Substance	[18]
Matrilin-2 (MATN2)	OTVDR68G	MATN2_HUMAN	Affects Response To Substance	[18]
Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5 (MACF1)	OTVIHD77	MACF1_HUMAN	Affects Response To Substance	[18]
Poly polymerase tankyrase-1 (TNKS)	OTVOUTPX	TNKS1_HUMAN	Affects Response To Substance	[18]
Ensconsin (MAP7)	OTVSSJ33	MAP7_HUMAN	Affects Response To Substance	[18]
Integrin beta-3 (ITGB3)	OTWCK1K6	ITB3_HUMAN	Increases Response To Substance	[146]
N-myc proto-oncogene protein (MYCN)	OTWD33K1	MYCN_HUMAN	Decreases Response To Substance	[147]
Sorbin and SH3 domain-containing protein 1 (SORBS1)	OTWH8762	SRBS1_HUMAN	Affects Response To Substance	[18]
Anamorsin (CIAPIN1)	OTWS90F9	CPIN1_HUMAN	Decreases Response To Substance	[148]
Inositol 1,4,5-trisphosphate receptor type 1 (ITPR1)	OTX7MWW1	ITPR1_HUMAN	Affects Response To Substance	[18]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1)	OTX8L3M5	SAHH2_HUMAN	Affects Response To Substance	[18]
Long-chain fatty acid transport protein 3 (SLC27A3)	OTXB60L7	S27A3_HUMAN	Affects Response To Substance	[18]
Insulin-like growth factor 1 receptor (IGF1R)	OTXJIF13	IGF1R_HUMAN	Affects Response To Substance	[149]
Estrogen receptor beta (ESR2)	OTXNR2WQ	ESR2_HUMAN	Increases Response To Substance	[150]
Coiled-coil domain-containing protein 6 (CCDC6)	OTXRQDYG	CCDC6_HUMAN	Decreases Response To Substance	[151]
Arginine vasopressin-induced protein 1 (AVPI1)	OTXSBR60	AVPI1_HUMAN	Affects Response To Substance	[18]
Carbamoyl-phosphate synthase , mitochondrial (CPS1)	OTXV8NSR	CPSM_HUMAN	Affects Response To Substance	[18]
Peripheral myelin protein 22 (PMP22)	OTXWYWCZ	PMP22_HUMAN	Affects Response To Substance	[18]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (HMG20B)	OTY94WRA	HM20B_HUMAN	Affects Response To Substance	[18]
Protein Niban 1 (NIBAN1)	OTYOLI12	NIBA1_HUMAN	Affects Response To Substance	[18]
LIM and calponin homology domains-containing protein 1 (LIMCH1)	OTYPC4XA	LIMC1_HUMAN	Affects Response To Substance	[18]
Galectin-3 (LGALS3)	OTYQT0ZI	LEG3_HUMAN	Affects Response To Substance	[18]
L-dopachrome tautomerase (DCT)	OTYVNTBG	TYRP2_HUMAN	Affects Response To Substance	[18]
PRA1 family protein 3 (ARL6IP5)	OTYZ6BEQ	PRAF3_HUMAN	Increases Response To Substance	[152]
DNA (DNMT3B)	OTZ0JCNP	DNM3B_HUMAN	Decreases Response To Substance	[135]
Calcitonin (CALCA)	OTZ11LHB	CALC_HUMAN	Decreases Response To Substance	[153]
Hephaestin (HEPH)	OTZ2F15Z	HEPH_HUMAN	Affects Response To Substance	[18]
Complement decay-accelerating factor (CD55)	OTZ3HWTO	DAF_HUMAN	Affects Response To Substance	[18]
Tissue factor pathway inhibitor 2 (TFPI2)	OTZCRWOR	TFPI2_HUMAN	Affects Response To Substance	[18]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Affects Response To Substance	[18]
Suppressor of tumorigenicity 7 protein (ST7)	OTZG8RC6	ST7_HUMAN	Affects Response To Substance	[18]
UPF0489 protein C5orf22 (C5ORF22)	OTZN0DCX	CE022_HUMAN	Affects Response To Substance	[18]
Alkaline phosphatase, placental type (ALPP)	OTZU4G9W	PPB1_HUMAN	Affects Response To Substance	[18]
Drebrin (DBN1)	OTZVKG8A	DREB_HUMAN	Affects Response To Substance	[18]

Indication(s) of Lapatinib

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[6]
Gastroesophageal junction adenocarcinoma	2B71	Approved	[7]
Melanoma	2C30	Approved	[7]

Lapatinib Interacts with 3 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Inhibitor	[155]
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[155]
Eukaryotic elongation factor 2 kinase (eEF-2K)	TT1QFLA	EF2K_HUMAN	Inhibitor	[156]

Lapatinib Interacts with 2 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[157]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[158]

Lapatinib Interacts with 4 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[159]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[160]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[159]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[160]

Lapatinib Interacts with 36 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Decreases Activity	[161]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[162]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Increases Expression	[163]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[163]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[163]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Increases Activity	[163]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[164]
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Decreases Activity	[161]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[165]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[166]
DNA topoisomerase 1 (TOP1)	OT51O0CF	TOP1_HUMAN	Decreases Expression	[167]
DNA topoisomerase 2-alpha (TOP2A)	OT6LPS08	TOP2A_HUMAN	Decreases Expression	[167]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[167]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[165]
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Decreases Activity	[168]
Receptor tyrosine-protein kinase erbB-3 (ERBB3)	OTRSST0A	ERBB3_HUMAN	Decreases Activity	[169]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Increases Secretion	[170]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[161]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Activity	[165]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Activity	[165]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Activity	[161]
DNA replication licensing factor MCM7 (MCM7)	OT6FXC6K	MCM7_HUMAN	Decreases Expression	[165]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[167]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[161]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[167]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[167]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[166]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Activity	[171]
GTPase KRas (KRAS)	OT78QCN8	RASK_HUMAN	Decreases Response To Substance	[172]
HLA class II histocompatibility antigen, DQ alpha 1 chain (HLA-DQA1)	OTC6GISG	DQA1_HUMAN	Increases ADR	[173]
Zinc finger protein SNAI1 (SNAI1)	OTDPYAMC	SNAI1_HUMAN	Decreases Response To Substance	[174]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Increases Metabolism	[167]
Cytochrome P450 3A7 (CYP3A7)	OTTCDHHM	CP3A7_HUMAN	Increases Metabolism	[167]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Decreases Response To Substance	[174]
Tenascin-X (TNXB)	OTVBWAV5	TENX_HUMAN	Increases ADR	[173]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)	OTVVI3UI	DQB1_HUMAN	Increases ADR	[173]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCJKUYN	CAOV3	Investigative	[1]
Adenocarcinoma	DC93UNY	A427	Investigative	[1]
Adenocarcinoma	DC51YQZ	NCIH1650	Investigative	[1]
Adenocarcinoma	DCJ2IA8	NCIH2122	Investigative	[1]
Adenocarcinoma	DC34QBY	NCIH520	Investigative	[1]
Adenocarcinoma	DCNDOQJ	COLO320DM	Investigative	[1]
Adenocarcinoma	DCM03AU	DLD1	Investigative	[1]
Adenocarcinoma	DCJMOCK	HCT116	Investigative	[1]
Adenocarcinoma	DCOR98A	HT29	Investigative	[1]
Amelanotic melanoma	DC7015V	A2058	Investigative	[1]
Malignant melanoma	DCREIRF	HT144	Investigative	[1]
Malignant melanoma	DCRV7CW	RPMI7951	Investigative	[1]
Malignant melanoma	DCX5LG3	UACC62	Investigative	[1]
Mesothelioma	DCIOBEW	MSTO	Investigative	[1]
Ovarian endometrioid adenocarcinoma	DCI7RNJ	A2780	Investigative	[1]
Ovarian serous cystadenocarcinoma	DCXGS8O	SK-OV-3	Investigative	[1]
Prostate carcinoma	DCE4HR5	LNCAP	Investigative	[1]
Prostate carcinoma	DCH65TQ	VCAP	Investigative	[1]
Breast and ovarian cancer syndrome	DCJUJ4V	UWB1289	Investigative	[175]
Breast and ovarian cancer syndrome	DCWLF6D	UWB1289+BRCA1	Investigative	[175]
Breast carcinoma	DCNL6VW	ZR751	Investigative	[175]
Breast carcinoma	DC2JMJ4	OCUBM	Investigative	[175]
Carcinoma	DCHC1VS	MDAMB436	Investigative	[175]
Colon adenocarcinoma	DCCXPRB	LOVO	Investigative	[175]
Rectal adenocarcinoma	DCSKTVU	SW837	Investigative	[175]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Etoposide FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6815).
• [4] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 075635.
• [5] ClinicalTrials.gov (NCT04356690) Etoposide in Patients With COVID-19 Infection. U.S. National Institutes of Health.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
• [7] Lapatinib FDA Label
• [8] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [9] Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J Biol Chem. 2007 Oct 12;282(41):29847-54.
• [10] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [11] Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol. 2018 Apr;92(4):1507-1524.
• [12] Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
• [13] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [14] New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines. Breast Cancer Res. 2006;8(1):R1. doi: 10.1186/bcr1362. Epub 2005 Dec 9.
• [15] Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells. Basic Clin Pharmacol Toxicol. 2015 Dec;117(6):383-91. doi: 10.1111/bcpt.12425. Epub 2015 Jun 30.
• [16] Identification of XAF1-MT2A mutual antagonism as a molecular switch in cell-fate decisions under stressful conditions. Proc Natl Acad Sci U S A. 2017 May 30;114(22):5683-5688. doi: 10.1073/pnas.1700861114. Epub 2017 May 15.
• [17] Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway. Blood. 2008 Apr 15;111(8):4365-74. doi: 10.1182/blood-2007-08-106336. Epub 2008 Feb 12.
• [18] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [19] Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate. 2005 Jan 1;62(1):61-8. doi: 10.1002/pros.20117.
• [20] Werner's syndrome lymphoblastoid cells are hypersensitive to topoisomerase II inhibitors in the G2 phase of the cell cycle. Mutat Res. 2000 Mar 20;459(2):123-33. doi: 10.1016/s0921-8777(99)00065-8.
• [21] Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma. Eur J Cancer. 2011 Sep;47(13):2068-76. doi: 10.1016/j.ejca.2011.04.021. Epub 2011 May 18.
• [22] Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death. J Biol Chem. 2002 Sep 6;277(36):33249-57. doi: 10.1074/jbc.M203036200. Epub 2002 Jun 21.
• [23] An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. Cancer Res. 2002 Oct 15;62(20):5888-96.
• [24] A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA. PLoS Med. 2008 May 20;5(5):e94. doi: 10.1371/journal.pmed.0050094.
• [25] Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2. Biochim Biophys Acta. 2014 Feb;1843(2):387-97. doi: 10.1016/j.bbamcr.2013.10.015. Epub 2013 Oct 31.
• [26] The Wnt signaling pathway regulates Nalm-16 b-cell precursor acute lymphoblastic leukemic cell line survival and etoposide resistance. Biomed Pharmacother. 2010 Jan;64(1):63-72. doi: 10.1016/j.biopha.2009.09.005. Epub 2009 Oct 27.
• [27] Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst. 2000 Jan 5;92(1):18-23. doi: 10.1093/jnci/92.1.18.
• [28] Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005 Jun 15;105(12):4752-8. doi: 10.1182/blood-2004-11-4544. Epub 2005 Feb 15.
• [29] Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
• [30] Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
• [31] Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
• [32] Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
• [33] Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
• [34] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [35] Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
• [36] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [37] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [38] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [39] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [40] Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
• [41] Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
• [42] Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
• [43] Development of in vitro 3D cell model from hepatocellular carcinoma (HepG2) cell line and its application for genotoxicity testing. Arch Toxicol. 2019 Nov;93(11):3321-3333. doi: 10.1007/s00204-019-02576-6. Epub 2019 Sep 21.
• [44] O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994 Feb;45(2):352-8.
• [45] The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther. 2000 Aug;294(2):480-7.
• [46] Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. Int J Biochem Mol Biol. 2016 Aug 5;7(2):27-47. eCollection 2016.
• [47] Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005 May 14;11(18):2748-53. doi: 10.3748/wjg.v11.i18.2748.
• [48] Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2. J Med Invest. 2005 Feb;52(1-2):41-8. doi: 10.2152/jmi.52.41.
• [49] Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines. Jpn J Cancer Res. 2001 Oct;92(10):1133-7. doi: 10.1111/j.1349-7006.2001.tb01069.x.
• [50] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [51] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [52] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [53] Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011 Jul 31;10:95. doi: 10.1186/1476-4598-10-95.
• [54] Effect of functionalized and non-functionalized nanodiamond on the morphology and activities of antioxidant enzymes of lung epithelial cells (A549). Chem Biol Interact. 2014 Oct 5;222:135-47.
• [55] Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol. 2005 Jul;25(13):5404-16. doi: 10.1128/MCB.25.13.5404-5416.2005.
• [56] Transcriptional repression of IKK by p53 in arsenite-induced GADD45 accumulation and apoptosis. Oncogene. 2019 Jan;38(5):731-746. doi: 10.1038/s41388-018-0478-7. Epub 2018 Sep 3.
• [57] The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem. 2004 May;260(1-2):129-35. doi: 10.1023/b:mcbi.0000026063.96267.98.
• [58] Profiling dose-dependent activation of p53-mediated signaling pathways by chemicals with distinct mechanisms of DNA damage. Toxicol Sci. 2014 Nov;142(1):56-73. doi: 10.1093/toxsci/kfu153. Epub 2014 Jul 30.
• [59] Estrogen regulation of apoptosis in osteoblasts. Physiol Behav. 2010 Feb 9;99(2):181-5. doi: 10.1016/j.physbeh.2009.04.025. Epub 2009 May 5.
• [60] Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer. 2003 Dec 20;107(6):929-40. doi: 10.1002/ijc.11503.
• [61] Lysosome Fe(2+) release is responsible for etoposide- and cisplatin-induced stemness of small cell lung cancer cells. Environ Toxicol. 2021 Aug;36(8):1654-1663. doi: 10.1002/tox.23161. Epub 2021 May 10.
• [62] Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer. 2008 Jan 15;122(2):433-43. doi: 10.1002/ijc.23049.
• [63] Responses of genes involved in cell cycle control to diverse DNA damaging chemicals in human lung adenocarcinoma A549 cells. Cancer Cell Int. 2005 Aug 24;5:28. doi: 10.1186/1475-2867-5-28.
• [64] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [65] Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. J Med Chem. 2011 Jan 27;54(2):580-90. doi: 10.1021/jm101150b. Epub 2010 Dec 27.
• [66] (-)-Xanthatin induces the prolonged expression of c-Fos through an N-acetyl-L-cysteine (NAC)-sensitive mechanism in human breast cancer MDA-MB-231 cells. J Toxicol Sci. 2013;38(4):547-57. doi: 10.2131/jts.38.547.
• [67] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [68] Basal and UV-induced MMP-1 expression are inhibited by p53 in human dermal fibroblasts. Exp Dermatol. 2008 Nov;17(11):939-45. doi: 10.1111/j.1600-0625.2008.00729.x. Epub 2008 Jun 14.
• [69] 2,3,7,8-tetrachlorodibenzo-p-dioxin counteracts the p53 response to a genotoxicant by upregulating expression of the metastasis marker agr2 in the hepatocarcinoma cell line HepG2. Toxicol Sci. 2010 Jun;115(2):501-12. doi: 10.1093/toxsci/kfq082. Epub 2010 Mar 18.
• [70] cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J Cell Sci. 1998 Mar;111 ( Pt 5):637-44. doi: 10.1242/jcs.111.5.637.
• [71] DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation. Cancer Sci. 2007 Jun;98(6):858-63. doi: 10.1111/j.1349-7006.2007.00476.x. Epub 2007 Apr 18.
• [72] [Influence of HMGB1/MAPK/m-TOR signaling pathway on cell autophagy and chemotherapy resistance in K562 cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016 Oct 28;41(10):1016-1023. doi: 10.11817/j.issn.1672-7347.2016.10.002.
• [73] p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem. 2003 Jun 27;278(26):23360-8. doi: 10.1074/jbc.M300771200. Epub 2003 Apr 10.
• [74] Expression and release of chemokines associated with apoptotic cell death in human promonocytic U937 cells and peripheral blood mononuclear cells. Eur J Immunol. 1999 Oct;29(10):3225-35. doi: 10.1002/(SICI)1521-4141(199910)29:10<3225::AID-IMMU3225>3.0.CO;2-0.
• [75] Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol. 2008 Dec;217(3):569-76. doi: 10.1002/jcp.21565.
• [76] Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II. J Biol Chem. 2015 Jun 5;290(23):14418-29. doi: 10.1074/jbc.M115.643015. Epub 2015 Apr 25.
• [77] Tumor protein translationally controlled 1 is a p53 target gene that promotes cell survival. Cell Cycle. 2013 Jul 15;12(14):2321-8. doi: 10.4161/cc.25404.
• [78] The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br J Haematol. 2003 Jan;120(2):315-24. doi: 10.1046/j.1365-2141.2003.03971.x.
• [79] Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.
• [80] Specific inhibition of rRNA transcription and dynamic relocation of fibrillarin induced by mercury. Exp Cell Res. 2000 Aug 25;259(1):225-38. doi: 10.1006/excr.2000.4923.
• [81] Regulation of genotoxic stress response by homeodomain-interacting protein kinase 2 through phosphorylation of cyclic AMP response element-binding protein at serine 271. Mol Biol Cell. 2010 Aug 15;21(16):2966-74. doi: 10.1091/mbc.E10-01-0015. Epub 2010 Jun 23.
• [82] Two distinct phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells. J Biol Chem. 2003 May 16;278(20):18092-100. doi: 10.1074/jbc.M300265200. Epub 2003 Mar 13.
• [83] MAP kinase-signaling controls nuclear translocation of tripeptidyl-peptidase II in response to DNA damage and oxidative stress. Biochem Biophys Res Commun. 2010 Aug 27;399(3):324-30. doi: 10.1016/j.bbrc.2010.06.133. Epub 2010 Jul 17.
• [84] Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem. 2005 Jan;38(1):50-7. doi: 10.1016/j.clinbiochem.2004.09.012.
• [85] "Exposure to the insecticides permethrin and malathion induces leukemia and lymphoma-associated gene aberrations in vitro". Toxicol In Vitro. 2017 Oct;44:17-26. doi: 10.1016/j.tiv.2017.06.013. Epub 2017 Jun 15.
• [86] CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway. Chem Biol Interact. 2016 Dec 25;260:1-12. doi: 10.1016/j.cbi.2016.10.014. Epub 2016 Oct 18.
• [87] Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res. 2004 Jan;2(1):53-61.
• [88] A molecular beacon approach to detecting RAD52 expression in response to DNA damage in human cells. Toxicol In Vitro. 2010 Mar;24(2):652-60. doi: 10.1016/j.tiv.2009.09.019. Epub 2009 Sep 30.
• [89] Nitric oxide inhibits apoptosis via AP-1-dependent CD95L transactivation. Cancer Res. 2000 May 1;60(9):2377-83.
• [90] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [91] DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. Int J Mol Med. 2006 Dec;18(6):1081-7.
• [92] Protein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells. PLoS One. 2009 Aug 7;4(8):e6552. doi: 10.1371/journal.pone.0006552.
• [93] Phosphorylation and stabilization of topoisomerase II protein by p38 mitogen-activated protein kinase sensitize breast cancer cells to its poisons. J Biol Chem. 2011 Oct 14;286(41):35883-35890. doi: 10.1074/jbc.M111.229260. Epub 2011 Aug 30.
• [94] Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma. Clin Cancer Res. 2007 Dec 1;13(23):7012-21. doi: 10.1158/1078-0432.CCR-06-2891.
• [95] Functional inactivation of triosephosphate isomerase through phosphorylation during etoposide-induced apoptosis in HeLa cells: potential role of Cdk2. Toxicology. 2010 Dec 5;278(2):224-8. doi: 10.1016/j.tox.2010.02.005. Epub 2010 Feb 10.
• [96] NF-B1 p50 promotes p53 protein translation through miR-190 downregulation of PHLPP1. Oncogene. 2014 Feb 20;33(8):996-1005. doi: 10.1038/onc.2013.8. Epub 2013 Feb 11.
• [97] A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015 May;43(5):404-413.e5. doi: 10.1016/j.exphem.2015.01.005. Epub 2015 Jan 26.
• [98] Chlorpyrifos Induces MLL Translocations Through Caspase 3-Dependent Genomic Instability and Topoisomerase II Inhibition in Human Fetal Liver Hematopoietic Stem Cells. Toxicol Sci. 2015 Oct;147(2):588-606. doi: 10.1093/toxsci/kfv153. Epub 2015 Jul 20.
• [99] The broken MLL gene is frequently located outside the inherent chromosome territory in human lymphoid cells treated with DNA topoisomerase II poison etoposide. PLoS One. 2013 Sep 25;8(9):e75871. doi: 10.1371/journal.pone.0075871. eCollection 2013.
• [100] Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway. Toxicol Appl Pharmacol. 2023 Sep 1;474:116625. doi: 10.1016/j.taap.2023.116625. Epub 2023 Jul 13.
• [101] Translation of cellular inhibitor of apoptosis protein 1 (c-IAP1) mRNA is IRES mediated and regulated during cell stress. RNA. 2004 Mar;10(3):469-81. doi: 10.1261/rna.5156804.
• [102] The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1. Mol Cancer Res. 2009 Jun;7(6):916-22. doi: 10.1158/1541-7786.MCR-08-0359. Epub 2009 Jun 2.
• [103] Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2. Cancer Sci. 2008 Aug;99(8):1693-8. doi: 10.1111/j.1349-7006.2008.00867.x.
• [104] Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Res. 2007 Dec 1;67(23):11317-26. doi: 10.1158/0008-5472.CAN-07-1088.
• [105] Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
• [106] [Expression and function of Ahi-1 gene in Jurkat cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Apr;17(2):445-9.
• [107] Expression of the RAI gene is conducive to apoptosis: studies of induction and interference. Exp Cell Res. 2007 Jul 15;313(12):2611-21. doi: 10.1016/j.yexcr.2007.05.006. Epub 2007 May 22.
• [108] Acetylation-dependent function of human single-stranded DNA binding protein 1. Nucleic Acids Res. 2015 Sep 18;43(16):7878-87. doi: 10.1093/nar/gkv707. Epub 2015 Jul 13.
• [109] A human short open reading frame (sORF)-encoded polypeptide that stimulates DNA end joining. J Biol Chem. 2014 Apr 18;289(16):10950-10957. doi: 10.1074/jbc.C113.533968. Epub 2014 Mar 7.
• [110] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [111] Comprehensive Landscape of Nrf2 and p53 Pathway Activation Dynamics by Oxidative Stress and DNA Damage. Chem Res Toxicol. 2017 Apr 17;30(4):923-933. doi: 10.1021/acs.chemrestox.6b00322. Epub 2016 Dec 16.
• [112] Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008 Mar;45(5):1470-6. doi: 10.1016/j.molimm.2007.08.013. Epub 2007 Oct 24.
• [113] Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. Toxicol Appl Pharmacol. 2016 Feb 1;292:1-7. doi: 10.1016/j.taap.2015.12.008. Epub 2015 Dec 18.
• [114] CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer. 2011 Mar 15;128(6):1316-26. doi: 10.1002/ijc.25466.
• [115] Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein. Cancer Biol Ther. 2004 Apr;3(4):377-81. doi: 10.4161/cbt.3.4.724. Epub 2004 Apr 17.
• [116] Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene. 2011 Jan 27;30(4):482-93. doi: 10.1038/onc.2010.435. Epub 2010 Sep 20.
• [117] CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006 Mar 18;6:75. doi: 10.1186/1471-2407-6-75.
• [118] Selective cell death of oncogenic Akt-transduced brain cancer cells by etoposide through reactive oxygen species mediated damage. Mol Cancer Ther. 2007 Aug;6(8):2178-87. doi: 10.1158/1535-7163.MCT-07-0111.
• [119] Overexpression of thymosin beta-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively. Carcinogenesis. 2006 May;27(5):936-44. doi: 10.1093/carcin/bgi316. Epub 2005 Dec 19.
• [120] Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
• [121] Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. doi: 10.1158/0008-5472.CAN-03-3675.
• [122] CD44 promotes resistance to apoptosis in human colon cancer cells. Exp Mol Pathol. 2004 Aug;77(1):18-25. doi: 10.1016/j.yexmp.2004.03.002.
• [123] Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem. 2005 Jul 29;280(30):27998-8006. doi: 10.1074/jbc.M503698200. Epub 2005 May 19.
• [124] Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther. 2006 Dec;5(12):3248-57. doi: 10.1158/1535-7163.MCT-06-0227.
• [125] Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer. 2007 Dec 1;121(11):2387-94. doi: 10.1002/ijc.22977.
• [126] Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int J Cancer. 2005 Jan 10;113(2):213-20. doi: 10.1002/ijc.20570.
• [127] RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines. Neuro Oncol. 2011 Dec;13(12):1265-76. doi: 10.1093/neuonc/nor129. Epub 2011 Aug 31.
• [128] Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair. Clin Cancer Res. 2011 Jul 1;17(13):4600-9. doi: 10.1158/1078-0432.CCR-10-2591. Epub 2011 May 24.
• [129] Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci. 2007 May;64(9):1137-44. doi: 10.1007/s00018-007-6510-7.
• [130] Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer. 2005 Aug 10;116(1):155-60. doi: 10.1002/ijc.20919.
• [131] S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3. Oncol Rep. 2008 Aug;20(2):325-32.
• [132] c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal. 2011 Mar 29;4(166):ra19. doi: 10.1126/scisignal.2001556.
• [133] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [134] Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
• [135] DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. Mol Cancer Res. 2008 Feb;6(2):243-9. doi: 10.1158/1541-7786.MCR-07-0373.
• [136] Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004 Feb 15;64(4):1403-10. doi: 10.1158/0008-5472.can-3263-2.
• [137] Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 2007 May 15;67(10):4860-8. doi: 10.1158/0008-5472.CAN-06-3096.
• [138] Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res. 2005 Oct 1;65(19):8628-34. doi: 10.1158/0008-5472.CAN-05-1059.
• [139] 4-benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKC. J Med Chem. 2011 Oct 13;54(19):6714-23. doi: 10.1021/jm2005892. Epub 2011 Sep 14.
• [140] Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells. Chem Res Toxicol. 2006 Jul;19(7):937-43. doi: 10.1021/tx0600595.
• [141] [Expression of C1QBP gene and its correlation with drug resistance in human resistance choriocarcinoma cell line]. Zhonghua Fu Chan Ke Za Zhi. 2014 Aug;49(8):616-20.
• [142] Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood. 2001 Aug 1;98(3):805-13. doi: 10.1182/blood.v98.3.805.
• [143] Regulation of multidrug resistance by ribosomal protein l6 in gastric cancer cells. Cancer Biol Ther. 2005 Feb;4(2):242-7. doi: 10.4161/cbt.4.2.1477. Epub 2005 Feb 20.
• [144] Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk / Bik. Oncogene. 2005 Nov 10;24(49):7369-80. doi: 10.1038/sj.onc.1208890.
• [145] Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res. 2008 Aug 15;14(16):5131-41. doi: 10.1158/1078-0432.CCR-08-0304.
• [146] Pro-apoptotic role of integrin 3 in glioma cells. J Neurochem. 2011 May;117(3):494-503. doi: 10.1111/j.1471-4159.2011.07219.x. Epub 2011 Mar 15.
• [147] Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene. 1999 Apr 29;18(17):2777-82. doi: 10.1038/sj.onc.1202859.
• [148] [Reversal of multidrug resistance of gastric cancer cells by down-regulation of CIAPIN1 with CIAPIN1 siRNA]. Mol Biol (Mosk). 2008 Jan-Feb;42(1):102-9.
• [149] Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther. 2005 Jan;12(1):90-100. doi: 10.1038/sj.cgt.7700775.
• [150] Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G?/M checkpoint signaling. Breast Cancer Res Treat. 2011 Jun;127(2):417-27. doi: 10.1007/s10549-010-1011-z. Epub 2010 Jul 10.
• [151] Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control. PLoS One. 2012;7(2):e31007. doi: 10.1371/journal.pone.0031007. Epub 2012 Feb 17.
• [152] JWA sensitizes P-glycoprotein-mediated drug-resistant choriocarcinoma cells to etoposide via JNK and mitochondrial-associated signal pathway. J Toxicol Environ Health A. 2009;72(11-12):774-81. doi: 10.1080/15287390902841649.
• [153] Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther. 2005 Nov;4(11):1226-33. doi: 10.4161/cbt.4.11.2093. Epub 2005 Nov 5.
• [154] UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3. Chem Biol Interact. 2019 Sep 1;310:108745. doi: 10.1016/j.cbi.2019.108745. Epub 2019 Jul 9.
• [155] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [156] Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813.
• [157] Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
• [158] The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
• [159] Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
• [160] Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
• [161] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [162] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [163] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [164] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [165] CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
• [166] Effects of lapatinib on cell proliferation and apoptosis in NB4 cells. Oncol Lett. 2018 Jan;15(1):235-242. doi: 10.3892/ol.2017.7342. Epub 2017 Nov 3.
• [167] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [168] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [169] Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.
• [170] Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
• [171] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [172] The K-Ras effector p38 MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation. J Biol Chem. 2017 Sep 8;292(36):15070-15079. doi: 10.1074/jbc.M117.779488. Epub 2017 Jul 24.
• [173] HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011 Feb 20;29(6):667-73. doi: 10.1200/JCO.2010.31.3197. Epub 2011 Jan 18.
• [174] Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. Int J Biochem Cell Biol. 2016 Feb;71:12-23. doi: 10.1016/j.biocel.2015.11.014. Epub 2015 Nov 28.
• [175] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.